Tagged with P

Thai Pharmaceutical Manufacturers Association TPMA is the main association bringing together the local manufacturers in Thailand. What do you consider to have been the main milestones and achievements since your inception? We haven’t reached any milestones yet. Our first milestone will be to open and free the pharmaceutical market in Thailand by breaking the…

PREMA Thailand PReMa was established in 2004 after a period of transformation to represent the growing role of its members, research-based companies. To begin with, could you explain us the main milestones and achievements of the organization? PReMA has been present in Thailand for 42 years. The association only changed and took…

Fundacion ExportAR Fundacion Export.Ar was formed in 1993. What was the vision behind the foundation of the company and why was it formed at that specific time? Argentina understood that the country had to create an agency to promote exports. We were a closed economy, and Argentina was trying to become an…

Phoenix How has Phoenix developed from being the family company that was founded seventy years ago into the successful corporate business it is today? I joined Phoenix in 1989, at that time Teosona (theophyline) had been recently introduced. It was a milestone in the respiratory disease treatment and after this launch,…

Astellas Pharma Ltd. South Africa The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an agency in South Africa under Pharmaplan from 1996. In 1997 I joined Pharmaplan as the Managing Director and ran the…

HLB Pharma Group Your entry into the Argentinean pharmaceutical market in 2004 was very unconventional, with your ‘holistic solution’ that had not been seen before in Argentina. Why was the time right in 2004 to start HLB Pharma? Hernán López Bernabó: We saw a special moment in Argentina to start a new company…

Bayer Schering Pharma Argentina The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What have been some of the challenges you have faced since that time? Argentina is a challenging market, and the system is very complex. This…

Ipsen Ukraine Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian operations of Ipsen been faring in comparison to the global performance of the company? Let me first provide you a…

Pharma Dynamics In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new dimension has Pharma Dynamics today in the South African pharma market, and how have you integrated the company’s growth in…

Lorenz Life Science Group In 2010, South Africa officially joined the BRICS grouping. The Indian and Russian work environments are familiar to you, considering your significant experience in these countries. How would you compare South Africa with its BRIC counterparts in terms of its regulatory environment? It has been eight months since I first…

Janssen Pharmaceutical Hungary Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag within the CEE region today? It is not the easiest question, as Hungary’s importance is changing from year to year.…

GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…